ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO2511

In-Depth Proteomic Analysis to Identify the Cellular Proteins and Secretome of Human Tubular Epithelial Cells with Fibrotic Injury

Session Information

Category: CKD (Non-Dialysis)

  • 2103 CKD (Non-Dialysis): Mechanisms


  • Kim, Ji Eun, Korea University Guro Hospital, Seoul, Korea (the Republic of)
  • Kim, Yong Chul, Seoul National University Hospital, Jongno-gu, Seoul, Korea (the Republic of)
  • Yoo, Kyung Don, Ulsan University Hospital, Ulsan, Korea (the Republic of)
  • Lee, Jae Wook, National Cancer Center, Goyang, Gyeonggi-do, Korea (the Republic of)
  • Kim, Dong Ki, Seoul National University Hospital, Jongno-gu, Seoul, Korea (the Republic of)
  • Kim, Yon Su, Seoul National University Hospital, Jongno-gu, Seoul, Korea (the Republic of)
  • Yang, Seung Hee, Seoul National University Hospital, Jongno-gu, Seoul, Korea (the Republic of)

Fibrosis is the major pathophysiology in the development of chronic kidney disease. While there are several proteomic studies to reveal the mechanism of renal fibrosis, the in-depth analysis which elucidate the repertoire of proteins expressed on cell or released into extracellular space are lacking.


To induce the fibrosis on kidney cells in stages, two different dose (1ng/ml and 2ng/ml) of TGFbeta were treated on primary cultured human renal proximal tubular epithelial cells (TECs). For global proteome and secretome profiling, liquid chromatography-tandem mass spectrometry based quantitative proteomic analysis were performed on isolated TECs and their media, respectively.


When comparing the cellular proteins expressed in control and in cells with fibrotic damage, we identified 691 and 1344 differentially expressed proteins (DEP) in low and high dose treated cells, respectively. And the DEPs in secretomes from low and high dose treated cells were 168 and 283, respectively. Then we identified overlapping 74 DEPs which showed significant difference in both cell and secretome analysis. Eleven proteins including NAMPT and KRT18 were decreased in same manner in both cell and secretome analysis, suggesting overall decrease in expression of these proteins with fibrosis. Seventeen proteins including STRAP and EIF3B were significantly decreased in cells while increased in secretome, representing the possible extracellular release of proteins with the response to fibrosis injury. There were 25 proteins including SERPINE1 and CTGF significantly elevated in both cell and secretome identified. And the other proteins which increased in cells and decreased in secretome were identified as 15 including PIEZO1 and ABCD4, which are presumably translocated into the cells with damage.


We identified different protein expression changes in cells and secretomes following fibrotic injury. Further studies are needed to validate the pathophysiological role of these proteins on kidney tubulointerstitial fibrosis.